UBE2C Induces Cisplatin Resistance via ZEB12-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells

Abstract EN

Objectives.

Cisplatin (DDP) is one of the most commonly used chemotherapeutic drugs for several cancers, including non-small-cell lung cancer (NSCLC).

However, resistance to DDP eventually develops, limiting its further application.

New therapy targets are urgently needed to reverse DDP resistance.

Methods.

The mRNA expression of UBE2C, ZEB1/2, ABCG2, and ERCC1 was analyzed by reverse transcription-polymerase chain reaction.

The protein levels of these molecules were analyzed by Western blotting and immunofluorescent staining.

Cell proliferation was detected by CCK8 and MTT assays.

Cell migration and invasion were analyzed by wound healing assay and Transwell assays.

Promoter activities and gene transcription were analyzed by luciferase reporter assay.

Results.

In this study, we examined the effect of UBE2C and ZEB1/2 expression levels in DDP-resistant cells of NSCLC.

We confirmed that aberrant expression of UBE2C and ZEB1/2 plays a critical role in repressing the DDP sensitivity to NSCLC cells.

Additionally, knockdown of UBE2C significantly sensitized resistant cells to DDP by repressing the expression of ZEB1/2.

Mechanistic investigations indicated that UBE2C transcriptionally regulated ZEB1/2 by accelerating promoter activity.

This study revealed that ZEB1/2 promotes the epithelial mesenchymal transition and expression of ABCG2 and ERCC1 to participate in UBE2C-mediated NSCLC DDP-resistant cell progression, metastasis, and invasion.

Conclusion.

UBE2C may be a novel therapy target for NSCLC for sensitizing cells to the chemotherapeutic agent DDP.